NASDAQ: OGIOrganigram Global Inc Stock
$1.53+0.10 (+6.99%)
Updated Aug 18, 2025
OGI Price
$1.53
Fair Value Price
N/A
Market Cap
$205.05M
52 Week Low
$0.85
52 Week High
$2.06
P/E
-170x
P/B
0.73x
P/S
1.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$163.37M
Earnings
$5.81M
Gross Margin
33.8%
Operating Margin
-0.9%
Profit Margin
3.6%
Debt to Equity
0.47
Operating Cash Flow
$2M
Beta
1.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OGI Overview
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OGI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
OGI
Ranked#49 of 58
Ranked#49 of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $31.25 | A | |
| $9.26 | A | |
| $23.42 | A |
Be the first to know about important OGI news, forecast changes, insider trades & much more!
OGI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OGI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OGI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OGI is good value based on its book value relative to its share price (0.73x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.25x)
P/B vs Industry Valuation
OGI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OGI due diligence checks available for Premium users.
Valuation
OGI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-170x
Industry
-13.84x
Market
35.94x
OGI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
2.25x
OGI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OGI's financial health
Profit margin
Revenue
$51.7M
Net Income
-$4.6M
Profit Margin
-8.9%
OGI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$412.1M
Liabilities
$130.7M
Debt to equity
0.47
OGI's short-term assets ($202.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OGI's short-term assets ($202.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OGI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OGI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$10.7M
Investing
-$6.9M
Financing
-$408.8k
OGI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OGI vs Pharmaceutical Stocks
Organigram Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.